Skip to content

Study · Observational study · 2014

3 results

Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials.

Raccah D, Lin J, Wang E, Germé M, Perfetti R, Bonadonna RC, de Pablos-Velasco P, Roussel R, Rosenstock J

Journal of diabetes and its complications14 Oct 2013Cited by 28 (Europe PMC)

PMID24246441 (opens in a new tab)DOI10.1016/j.jdiacomp.2013.10.003 (opens in a new tab)PepBankPUB-24246441
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with diabetes on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without symptomatic hypoglycemia than rapid-acting insulin.

    In plain wordsIn patients with diabetes on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without symptomatic hypoglycemia than rapid-acting insulin.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c below 7% without symptomatic hypoglycemia
    Study

    n: not reported in source

    Comparator
    Once-daily rapid-acting insulin added to basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    1.9
    lixisenatide versus rapid-acting insulin
    95% CI lower
    1.01
    odds ratio
    95% CI upper
    3.55
    odds ratio
    P
    0.0455
    comparison

    Source sentences

    Summary
    In the matched population, Basal+LIXI was twice as likely to reach composite outcomes of glycated haemoglobin (HbA1c) <7% and no symptomatic hypoglycaemia compared with the Basal+RAI group (odds ratio [OR]: 1.90; 95% confidence interval [CI]: 1.01, 3.55; P=0.0455)
    2 context sentences
    Summary · context
    Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin+insulin glulisine (n=3) or basal insulin+LIXI (n=2).
    Summary · context
    Patients in the Basal+LIXI cohort were matched to patients in the Basal+RAI cohort using propensity score matching.
  2. 02HumanObservational studyEfficacy outcome

    In patients with diabetes on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without severe hypoglycemia than rapid-acting insulin.

    In plain wordsIn patients with diabetes on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without severe hypoglycemia than rapid-acting insulin.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c below 7% without severe hypoglycemia
    Study

    n: not reported in source

    Comparator
    Once-daily rapid-acting insulin added to basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    1.97
    lixisenatide versus rapid-acting insulin
    CI lower
    1.06
    odds ratio
    CI upper
    3.66
    odds ratio
    P
    0.0311
    comparison

    Source sentences

    Summary
    as well as HbA1c <7% and no severe hypoglycaemia (OR: 1.97; 95 CI: 1.06, 3.66; P=0.0311).
    2 context sentences
    Summary · context
    Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin+insulin glulisine (n=3) or basal insulin+LIXI (n=2).
    Summary · context
    Patients in the Basal+LIXI cohort were matched to patients in the Basal+RAI cohort using propensity score matching.
  3. 03HumanObservational studyEfficacy outcome

    In patients on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without weight gain or symptomatic hypoglycemia than rapid-acting insulin.

    In plain wordsIn patients on basal insulin, lixisenatide was linked to greater HbA1c <7% attainment without weight gain or symptomatic hypoglycemia than rapid-acting insulin.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c below 7%, no weight gain and no symptomatic hypoglycemia
    Study

    n: not reported in source

    Comparator
    Once-daily rapid-acting insulin added to basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    2.58
    lixisenatide versus rapid-acting insulin
    95% CI lower
    1.23
    odds ratio
    95% CI upper
    5.4
    odds ratio
    P
    0.0119
    comparison

    Source sentences

    Summary
    Furthermore, Basal+LIXI was more than twice as likely to reach HbA1c <7%, no weight gain and no symptomatic hypoglycaemia (OR: 2.58; 95% CI: 1.23, 5.40; P=0.0119).
    2 context sentences
    Summary · context
    Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin+insulin glulisine (n=3) or basal insulin+LIXI (n=2).
    Summary · context
    Patients in the Basal+LIXI cohort were matched to patients in the Basal+RAI cohort using propensity score matching.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.